AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Calmodulin-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.

Key features that set our library apart include:

  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P0DP23

UPID:

CALM1_HUMAN

Alternative names:

-

Alternative UPACC:

P0DP23; P02593; P62158; P70667; P99014; Q13942; Q53S29; Q61379; Q61380; Q96HK3

Background:

Calmodulin-1 plays a pivotal role in calcium signal transduction, influencing the activity of numerous enzymes, ion channels, and proteins. Its interaction with calcium is essential for its activation, impacting processes such as muscle contraction, cell division, and cardiac function. The protein's involvement in regulating the centrosome cycle and cytokinesis underscores its importance in cellular integrity and division.

Therapeutic significance:

Calmodulin-1 mutations are linked to life-threatening cardiac conditions like Ventricular tachycardia, catecholaminergic polymorphic, 4, and Long QT syndrome 14. These associations highlight the protein's critical role in cardiac electrical activity and present it as a potential target for therapeutic intervention in arrhythmogenic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.